Developer docs
API playgroundTry for free, no card

Search company profiles

MLA Diagnostics

Full company profile

uuid000cn59

Namestring
MLA Diagnostics
Legal namestring
MLA Diagnostics
Websiteurl
mladx.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

MLA Diagnostics is a Dutch molecular diagnostics company founded in 2019 and headquartered at the Brightlands Maastricht Health Campus in Maastricht, Netherlands. The company is developing a prognostic test for early-stage (Stage I and Stage II) cutaneous melanoma, targeting the clinical gap that roughly 20–30% of early-stage melanoma patients classified as low-risk by classical indicators (tumor thickness, ulceration) subsequently develop recurrence or metastasis. The test detects methylation of the LY75 (lymphocyte antigen 75) gene promoter using methylation-specific PCR (msPCR) and integrates that epigenetic signal with patient clinical and pathological parameters into a multi-parameter risk assessment tool. The assay is designed to drop into existing PCR/qPCR-based workflows in clinical pathology laboratories, so it does not require new instrumentation at customer sites.

The company is pre-revenue and is pursuing CE mark certification and clinical trials as the gating milestones for commercialization. Its intended go-to-market is B2B enterprise field sales to clinical pathology labs and treating clinicians (dermatologists, pathologists, oncologists), with revenue expected to come from one-time licensing or sale of the molecular test/service once regulatory clearance is obtained. There is no publicly disclosed pricing. Ownership is private and venture-backed; MLA Diagnostics was co-founded by venture builder NLC Health Ventures, Brightlands Life Science Ventures, Maastricht University academic Prof. Dr. Manon van Engeland, and CEO Egbert Smit, PhD, alongside an in-house R&D, quality/regulatory, and fractional finance team of roughly 1–10 people.

MLA Diagnostics has assembled a layered financing stack combining non-dilutive Dutch and European grants (MIT Haalbaarheid, EIT Headstart, LIOF LBDF POP, Rabobank Innovation Loan, RVO VFF, KWF Kankerbestrijding) with equity from NLC Health Ventures (via the €2.2M Momentum fund in 2020 and a follow-on in 2023) and Brightlands Life Science Ventures, alongside co-investment from LIOF. A strategic seven-figure round closed in November 2023 explicitly to advance clinical trials. Scientific and commercial partnerships with Maastricht University (biomarker discovery), Pathologie DNA (methylation assay development), KEMTA and HI-NL (health technology assessment and reimbursement strategy), and MSD/UtrechtInc (early commercial coaching) further scaffold the technical and market-access development path.

Short descriptiontext

MLA Diagnostics is a Dutch molecular diagnostics startup developing a DNA methylation-based prognostic test for early-stage melanoma, targeting clinical pathology labs and treating clinicians with an LY75 biomarker assay designed to integrate into existing laboratory workflows.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMaastricht, Netherlands
HQ citystring
Maastricht
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
melanoma prognostic tests, DNA methylation diagnostics, cancer biomarker assays, epigenetic molecular diagnostics, melanoma risk assessment
Industry3 codes
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Molecular Diagnostics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Molecular Diagnostic Test Sales
TypeOne Time License
Description

Pre-revenue company developing a DNA methylation-based diagnostic test for melanoma prognosis. Revenue model will likely involve selling diagnostic test kits/services to clinical pathology labs and healthcare institutions once CE mark is obtained and clinical trials are completed.

mladx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

MLA Diagnostics develops a DNA methylation-based molecular diagnostic test that detects methylation of the LY75 gene promoter to discriminate between low- and high-risk melanoma disease, predicting recurrence risk within 5 years. The test integrates into standard clinical pathology laboratory workflows and is enriched with patient clinical and pathological parameters to support clinicians in tailoring treatment intensity for early-stage melanoma patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Identifies high-risk patients among early-stage melanoma patients who may not present with high-risk classical indicators
Product overview1 text field

MLA Diagnostics offers a unified core product: a multi-parameter melanoma risk assessment tool that combines a DNA methylation-based molecular test (the LY75 Methylation Test) with clinical and pathological parameters. The LY75 Methylation Test serves as the epigenetic foundation of the tool, detecting methylation of the lymphocyte antigen 75 (LY75) gene promoter to predict poor clinical outcomes, while the integrated multi-parameter framework enriches this with patient clinical data for improved prognostic assessment of melanoma patients.

Product and service1 record
1Melanoma Risk Assessment Tool
CategoryMolecular Diagnostics / Cancer Prognostics
Description

A multi-parameter non-invasive melanoma risk assessment tool that identifies individuals at high risk of metastasis or recurrence. Using epigenetic tumor information (DNA methylation of the LY75 gene promoter) enriched with patient clinical and pathological parameters, it provides a more accurate prognosis to guide clinicians in tailoring treatment intensity and ensuring precise, personalized patient care. Targeted at clinical pathology labs and healthcare providers (dermatologists, pathologists, oncologists) for early-stage (Stage I/II) melanoma patients.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-31
Description

Teaming up with Maastricht University in a TKI academic project for discovery of clinically relevant methylation markers. Prof. Manon van Engeland is Professor of Pathobiology of Cancer at Maastricht University Medical Center.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-12-23
Description

Top-level diagnostics specialists collaborating with MLA Diagnostics in a MIT R&D samenwerkings research project to improve melanoma diagnostics and prognostics using methylation-based assays.

3KEMTA (Clinical Epidemiology & Medical Technology Assessment)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-10-30
Description

Collaboration partner in LBDF POP Health Technology Assessment project consisting of patient journey inventory, health economic modelling, and expert round table sessions.

mladx.com
4HI-NL (Health Innovation Netherlands)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-10-30
Description

Health innovation network partner in LBDF POP Health Technology Assessment project supporting health economic modelling and reimbursement strategy.

mladx.com
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2019-08-16
Description

MSD LAB1891 and UtrechtInc partnered to support 3 early stage startups selected by MSD. MLA Diagnostics gained valuable clinical insights into pharma drivers and interests in biomarker applications, companion diagnostics, predictive biomarkers, and personalized medicine through coaching, workshops, and access to global network.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1NeraCare
TypeDirect peer
Description

NeraCare is a German-European molecular diagnostics company developing the DecisionDx-Melanoma-related prognostic assays (MelaGenix) for early-stage melanoma, serving the same European dermatology/pathology customer base with a similar prognostic positioning to MLA Diagnostics.

TypeEmerging player
Description

VolitionRx is a US-based epigenetics diagnostics company developing Nu.Q blood-based cancer detection tests using nucleosome methylation biomarkers - comparable to MLA as an emerging methylation-based diagnostics developer operating in oncology, though broader than the melanoma niche.

TypeDirect peer
Description

Epigenomics AG is a German molecular diagnostics company specializing in DNA methylation-based cancer detection (Epi proColon for colorectal cancer), directly comparable to MLA on platform technology (DNA methylation biomarkers), workflow integration into clinical labs, and oncology focus.

TypeBroad incumbent
Description

Exact Sciences (COLOGUARD) commercializes Prof. van Engeland's NDRG4 methylation biomarker for colorectal cancer screening and has built a global footprint in methylation-based IVD - relevant to MLA via shared scientific lineage of its co-founder and as a benchmark for methylation-biomarker commercial scale.

TypeDirect peer
Description

SkylineDx is a Dutch molecular diagnostics company developing prognostic gene-expression tests for melanoma (e.g., DecisionDx-Melanoma via CP-GEP), directly competing with MLA Diagnostics in early-stage melanoma recurrence risk assessment for dermatology and pathology labs in Europe.

TypeBroad incumbent
Description

NeoGenomics is a US-based oncology-focused clinical lab and molecular diagnostics services provider with broad cancer genetic and methylation test offerings - comparable as an incumbent cancer diagnostics player whose footprint and payer contracts could compete with MLA's pathology-lab channel.

TypeDirect peer
Description

Castle Biosciences is a US-based molecular diagnostics company whose lead product DecisionDx-Melanoma is a gene-expression test predicting metastasis risk in early-stage melanoma patients, making it the most established direct competitor to MLA's LY75 methylation prognostic test.

TypeBroad incumbent
Description

Myriad Genetics is an established molecular diagnostics company with oncology genetic tests (including melanoma risk/gene panels) and broad lab infrastructure - representative of larger incumbents that could enter or displace targeted melanoma prognostic tests like MLA's.

TypeEmerging player
Description

MdxHealth is a Belgium/US molecular diagnostics company offering methylation-based urology and oncology tests (SelectMDx, ConfirmMDx), comparable to MLA as an emerging European molecular diagnostics player using epigenetic biomarkers targeting specialized oncology indications.

TypeDirect peer
Description

DermTech is a US-based molecular diagnostics company offering non-invasive genomic skin tests, including melanoma detection from adhesive skin samples - adjacent to MLA's melanoma prognostic space with overlap in dermatology lab adoption channels and epigenetic/molecular skin cancer diagnostics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MLA Diagnostics

Molecular Diagnosticsmladx.com

MLA Diagnostics is a Dutch molecular diagnostics startup developing a DNA methylation-based prognostic test for early-stage melanoma, targeting clinical pathology labs and treating clinicians with an LY75 biomarker assay designed to integrate into existing laboratory workflows.

What MLA Diagnostics does

MLA Diagnostics is a Dutch molecular diagnostics company founded in 2019 and headquartered at the Brightlands Maastricht Health Campus in Maastricht, Netherlands. The company is developing a prognostic test for early-stage (Stage I and Stage II) cutaneous melanoma, targeting the clinical gap that roughly 20–30% of early-stage melanoma patients classified as low-risk by classical indicators (tumor thickness, ulceration) subsequently develop recurrence or metastasis. The test detects methylation of the LY75 (lymphocyte antigen 75) gene promoter using methylation-specific PCR (msPCR) and integrates that epigenetic signal with patient clinical and pathological parameters into a multi-parameter risk assessment tool. The assay is designed to drop into existing PCR/qPCR-based workflows in clinical pathology laboratories, so it does not require new instrumentation at customer sites.

The company is pre-revenue and is pursuing CE mark certification and clinical trials as the gating milestones for commercialization. Its intended go-to-market is B2B enterprise field sales to clinical pathology labs and treating clinicians (dermatologists, pathologists, oncologists), with revenue expected to come from one-time licensing or sale of the molecular test/service once regulatory clearance is obtained. There is no publicly disclosed pricing. Ownership is private and venture-backed; MLA Diagnostics was co-founded by venture builder NLC Health Ventures, Brightlands Life Science Ventures, Maastricht University academic Prof. Dr. Manon van Engeland, and CEO Egbert Smit, PhD, alongside an in-house R&D, quality/regulatory, and fractional finance team of roughly 1–10 people.

MLA Diagnostics has assembled a layered financing stack combining non-dilutive Dutch and European grants (MIT Haalbaarheid, EIT Headstart, LIOF LBDF POP, Rabobank Innovation Loan, RVO VFF, KWF Kankerbestrijding) with equity from NLC Health Ventures (via the €2.2M Momentum fund in 2020 and a follow-on in 2023) and Brightlands Life Science Ventures, alongside co-investment from LIOF. A strategic seven-figure round closed in November 2023 explicitly to advance clinical trials. Scientific and commercial partnerships with Maastricht University (biomarker discovery), Pathologie DNA (methylation assay development), KEMTA and HI-NL (health technology assessment and reimbursement strategy), and MSD/UtrechtInc (early commercial coaching) further scaffold the technical and market-access development path.

MLA Diagnostics firmographics

Firmographics
Name
MLA Diagnostics
Legal name
MLA Diagnostics
Website
https://mladx.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
MLA Diagnostics is a Dutch molecular diagnostics startup developing a DNA methylation-based prognostic test for early-stage melanoma, targeting clinical pathology labs and treating clinicians with an LY75 biomarker assay designed to integrate into existing laboratory workflows.
Ownership category
akta.pro rank

MLA Diagnostics industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)

Keywords

  • Melanoma prognostic tests
  • DNA methylation diagnostics
  • Cancer biomarker assays
  • Epigenetic molecular diagnostics
  • Melanoma risk assessment

Where MLA Diagnostics is headquartered

Location

Headquarters

HQ city
Maastricht
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

MLA Diagnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Molecular Diagnostic Test Sales: Pre-revenue company developing a DNA methylation-based diagnostic test for melanoma prognosis. Revenue model will likely involve selling diagnostic test kits/services to clinical pathology labs and healthcare institutions once CE mark is obtained and clinical trials are completed.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

MLA Diagnostics product offering

Product offering

Core offering

MLA Diagnostics develops a DNA methylation-based molecular diagnostic test that detects methylation of the LY75 gene promoter to discriminate between low- and high-risk melanoma disease, predicting recurrence risk within 5 years. The test integrates into standard clinical pathology laboratory workflows and is enriched with patient clinical and pathological parameters to support clinicians in tailoring treatment intensity for early-stage melanoma patients.

Product overview

MLA Diagnostics offers a unified core product: a multi-parameter melanoma risk assessment tool that combines a DNA methylation-based molecular test (the LY75 Methylation Test) with clinical and pathological parameters. The LY75 Methylation Test serves as the epigenetic foundation of the tool, detecting methylation of the lymphocyte antigen 75 (LY75) gene promoter to predict poor clinical outcomes, while the integrated multi-parameter framework enriches this with patient clinical data for improved prognostic assessment of melanoma patients.

Differentiator

Problem solved

Functional benefit

Products and services

  • Melanoma Risk Assessment Tool A multi-parameter non-invasive melanoma risk assessment tool that identifies individuals at high risk of metastasis or recurrence. Using epigenetic tumor information (DNA methylation of the LY75 gene promoter) enriched with patient clinical and pathological parameters, it provides a more accurate prognosis to guide clinicians in tailoring treatment intensity and ensuring precise, personalized patient care. Targeted at clinical pathology labs and healthcare providers (dermatologists, pathologists, oncologists) for early-stage (Stage I/II) melanoma patients.

Quantifiable outcome

  • Identifies high-risk patients among early-stage melanoma patients who may not present with high-risk classical indicators

Companies that use MLA Diagnostics

Customer profile

Segments1 record

Ideal customer profiles1 record

MLA Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

MLA Diagnostics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Maastricht UniversitycoreStrategic or Co-development Partner · 31 January 2022Teaming up with Maastricht University in a TKI academic project for discovery of clinically relevant methylation markers. Prof. Manon van Engeland is Professor of Pathobiology of Cancer at Maastricht University Medical Center.
  • Pathologie DNAcoreStrategic or Co-development Partner · 23 December 2020Top-level diagnostics specialists collaborating with MLA Diagnostics in a MIT R&D samenwerkings research project to improve melanoma diagnostics and prognostics using methylation-based assays.
  • KEMTA (Clinical Epidemiology & Medical Technology Assessment)minorStrategic or Co-development Partner · 30 October 2019Collaboration partner in LBDF POP Health Technology Assessment project consisting of patient journey inventory, health economic modelling, and expert round table sessions.
  • HI-NL (Health Innovation Netherlands)minorStrategic or Co-development Partner · 30 October 2019Health innovation network partner in LBDF POP Health Technology Assessment project supporting health economic modelling and reimbursement strategy.
  • MSD LAB1891 / UtrechtIncminorGTM or Marketing Partner · 16 August 2019MSD LAB1891 and UtrechtInc partnered to support 3 early stage startups selected by MSD. MLA Diagnostics gained valuable clinical insights into pharma drivers and interests in biomarker applications, companion diagnostics, predictive biomarkers, and personalized medicine through coaching, workshops, and access to global network.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

MLA Diagnostics competitors and assessment

Company assessment

Direct peers

  • NeraCare: NeraCare is a German-European molecular diagnostics company developing the DecisionDx-Melanoma-related prognostic assays (MelaGenix) for early-stage melanoma, serving the same European dermatology/pathology customer base with a similar prognostic positioning to MLA Diagnostics.
  • Epigenomics AG: Epigenomics AG is a German molecular diagnostics company specializing in DNA methylation-based cancer detection (Epi proColon for colorectal cancer), directly comparable to MLA on platform technology (DNA methylation biomarkers), workflow integration into clinical labs, and oncology focus.
  • SkylineDx: SkylineDx is a Dutch molecular diagnostics company developing prognostic gene-expression tests for melanoma (e.g., DecisionDx-Melanoma via CP-GEP), directly competing with MLA Diagnostics in early-stage melanoma recurrence risk assessment for dermatology and pathology labs in Europe.
  • Castle Biosciences: Castle Biosciences is a US-based molecular diagnostics company whose lead product DecisionDx-Melanoma is a gene-expression test predicting metastasis risk in early-stage melanoma patients, making it the most established direct competitor to MLA's LY75 methylation prognostic test.
  • DermTech: DermTech is a US-based molecular diagnostics company offering non-invasive genomic skin tests, including melanoma detection from adhesive skin samples - adjacent to MLA's melanoma prognostic space with overlap in dermatology lab adoption channels and epigenetic/molecular skin cancer diagnostics.

Emerging players

  • VolitionRx: VolitionRx is a US-based epigenetics diagnostics company developing Nu.Q blood-based cancer detection tests using nucleosome methylation biomarkers - comparable to MLA as an emerging methylation-based diagnostics developer operating in oncology, though broader than the melanoma niche.
  • MdxHealth: MdxHealth is a Belgium/US molecular diagnostics company offering methylation-based urology and oncology tests (SelectMDx, ConfirmMDx), comparable to MLA as an emerging European molecular diagnostics player using epigenetic biomarkers targeting specialized oncology indications.

Broad incumbents

  • Exact Sciences: Exact Sciences (COLOGUARD) commercializes Prof. van Engeland's NDRG4 methylation biomarker for colorectal cancer screening and has built a global footprint in methylation-based IVD - relevant to MLA via shared scientific lineage of its co-founder and as a benchmark for methylation-biomarker commercial scale.
  • NeoGenomics: NeoGenomics is a US-based oncology-focused clinical lab and molecular diagnostics services provider with broad cancer genetic and methylation test offerings - comparable as an incumbent cancer diagnostics player whose footprint and payer contracts could compete with MLA's pathology-lab channel.
  • Myriad Genetics: Myriad Genetics is an established molecular diagnostics company with oncology genetic tests (including melanoma risk/gene panels) and broad lab infrastructure - representative of larger incumbents that could enter or displace targeted melanoma prognostic tests like MLA's.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

MLA Diagnostics compliance and trust

Trust signal

Compliance1 record

MLA Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MLA Diagnostics leadership team

Management profile

Number of profiles

Profiles6 records

MLA Diagnostics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MLA Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MLA Diagnostics

What does MLA Diagnostics do?

MLA Diagnostics develops a DNA methylation-based molecular diagnostic test that detects methylation of the LY75 gene promoter to discriminate between low- and high-risk melanoma disease, predicting recurrence risk within 5 years. The test integrates into standard clinical pathology laboratory workflows and is enriched with patient clinical and pathological parameters to support clinicians in tailoring treatment intensity for early-stage melanoma patients.

Is MLA Diagnostics a public or private company?

MLA Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was MLA Diagnostics founded?

MLA Diagnostics was founded in 2019. It employs 1 to 10 people.

Where is MLA Diagnostics based?

MLA Diagnostics is headquartered in Maastricht, Netherlands, in the Europe region.

How does MLA Diagnostics make money?

One revenue line is on record: molecular Diagnostic Test Sales.

Who are MLA Diagnostics's main competitors?

Direct peers on record are NeraCare, Epigenomics AG, SkylineDx, Castle Biosciences and DermTech. Emerging players are VolitionRx and MdxHealth. Broad incumbents are Exact Sciences, NeoGenomics and Myriad Genetics.

Does MLA Diagnostics have an API?

No public API is recorded for MLA Diagnostics.

What industry is MLA Diagnostics in?

MLA Diagnostics's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays), with a secondary code of HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals